TOP CANNABIS STOCK – GW PHARMA (GWPH – 2000% REVENUE GROWTH)

TOP CANNABIS STOCK – GW PHARMA (GWPH – 2000% REVENUE GROWTH)

Make money, learn how to trade stocks and invest in the stock market with everything you need to know about the fastest growing stocks & cryptocurrencies to invest in 2021!

► Learn To Trade: https://www.tradeinplaces.com/
► Start Trading Today: http://partners.etoro.com/A73672_TCli…
► Follow Me On My Travels With Instagram: https://www.instagram.com/tradeinplaces/

CHECK OUT THE BEST STOCKS TO INVEST IN NOW 👇

📒 Read My Latest Blog Article – Should You Buy Canopy Growth?
https://www.tradeinplaces.com/single-post/canopy-growth-cannabis-stock

🎥 Watch My Latest Video – Is Tilray The Best Cannabis Stock?

VIDEO SUMMARY 📜

I like Tilray, Aurora Cannabis & Canopy Growth but my favourite cannabis stock is GW Pharmaceuticals! So should you invest in the cannabis sector? is GW the best cannabis stock? Here are the key reasons why it’s one of my favourite stock picks!

FIRSTLY! Unlike other cannabis companies, GW Pharma considers itself more of a healthcare business and Rather than relying on the growth of recreational marijuana use, the company is specialising in producing breakthrough cannabinoid treatments such as the hugely successful Epidiolex. This is the only FDA approved cannabinoid on the market and is the key reason why GW’s revenues rose almost 2000% from 2018 to 2019. Growth has slowed down but still clocked in at 130% in 2020 which is about the same as Virgin Galactic and roughly triple other growth stocks like Nio, Beyond Meat & Crowdstrike! Despite this impressive growth, the stock fell 50% from it’s high in May and despite bouncing back – still trades around 25% off it’s all time high! I get why Investors might be worried about this deceleration in revenue growth, however 130% on revenue of half a billion is as good as you’ll find in the stock market! And this figure was almost certainly impacted by the pandemic and therefore could remain steady going forward!

SECONDLY! I feel really optimistic about GW’s growth prospects for a number of reasons including the fact that right now, GW gets almost 90% of their revenue from the US. However, their hit drug “Epidiolex” has recently been approved in Europe and GW is slowly rolling out their operations across the UK, Germany, Italy, Spain & France. Yes, the companies reach is getting larger but GW is also diversifying away from over-relying on hit drug Epidiolex thanks to their exciting pipeline of treatments. Not only is Epidiolex seeking approval for conditions beyond epilepsy and dravet syndrome, Sativex & CBDV are tipped to gain approval for treating conditions such as Schizophrenia, MS, Autism, PTSD and other neurological disorders. Although its high risk buying a pharmaceutical stock based on treatments that have yet to be cleared, GW has a good track record for getting approval having been the first company to get FDA approval for a cannabis-based drug.

Therefore, not only is the stock of GW undervalued vs other popular growth stocks, I believe that the company will benefit from good news on it’s upcoming phase 2 and phase 3 trials as well its unique positioning within cannabis & biotech which are likely to remain 2 red hot industries over the next couple of years!

𝗗𝗜𝗦𝗖𝗟𝗔𝗜𝗠𝗘𝗥: All trading involves risk. Only invest money that you can afford to lose and remember that past performance doesn’t necessarily guarantee future results. Everything posted by me is for educational purposes only. I am not a financial advisor and no information in these videos or on my website should be considered as financial advice.

#cannabis #cannabisstocks #gwpharma #growthstocks #stockpick #stocks #beststocks #stocks2021 #cryptocurrency #crypto